Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors
- Conditions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2010-08-09
- Target Recruit Count
- 30
- Registration Number
- NCT00368914
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 121
- Registration Number
- NCT00369382
- Locations
- 🇨🇭
Pfizer Investigational Site, Bern, Switzerland
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders
- Conditions
- Interventions
- Procedure: Allogeneic Bone Marrow TransplantationDrug: CyclophosphamideDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: Mycophenolate MofetilProcedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationDrug: SirolimusDrug: TacrolimusRadiation: Total-Body Irradiation
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00358657
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸The Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States
Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- University of Regensburg
- Target Recruit Count
- 525
- Registration Number
- NCT00355862
- Locations
- 🇩🇪
Regensburg University, Regensburg, Bavaria, Germany
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2014-04-14
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 25
- Registration Number
- NCT00353301
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
TBI Dose De-escalation for Fanconi Anemia
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 83
- Registration Number
- NCT00352976
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Pilot Study for HLA Identical Living Donor Renal Transplant Recipients
- Conditions
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 20
- Registration Number
- NCT00352092
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
- Conditions
- Interventions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 11
- Registration Number
- NCT00350181
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Conditions
- Interventions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 100
- Registration Number
- NCT00346918
- Locations
- 🇨🇭
University Hospital, Zurich, Switzerland
Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2017-04-21
- Target Recruit Count
- 5
- Registration Number
- NCT00346151
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.